Theralase Technologies develops photodynamic anti-cancer therapies, pairing ruthenium-based photosensitizers with laser systems that measure tissue response during treatment.
Theralase released unaudited interim consolidated financial statements for the six months ended June 30, 2026. The company reported a net loss of $2,093,926 and cash of $5,260,832, while Study II had enrolled 95 participants, assessed 89, and recorded a 65.2% complete response rate.
Theralase closed a brokered private placement of 14,812,500 units at C$0.24 per unit, generating C$3,555,000 in gross proceeds. Research Capital Corporation led the financing.
Theralase Technologies Inc. enters an agreement with Research Capital Corporation for a brokered private placement of units. Research Capital serves as sole agent and bookrunner, with units priced at C$0.24 and offering proceeds ranging from a minimum of C$3 million to a maximum of C$5 million.
Theralase closes a previously announced brokered private placement for approximately C$4.6 million, alongside a concurrent non-brokered private placement. The two offerings total approximately C$4.76 million.
